NASDAQ:PRTK - Paratek Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.55 +0.03 (+0.66 %)
(As of 05/20/2019 07:24 AM ET)
Previous Close$4.52
Today's Range$4.26 - $4.65
52-Week Range$4.26 - $12.30
Volume546,260 shs
Average Volume284,169 shs
Market Capitalization$147.51 million
P/E RatioN/A
Dividend YieldN/A
Beta1.52
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PRTK
Previous SymbolNASDAQ:TSPT
CUSIP89354M10
Phone617-807-6600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.12 million
Book Value$0.49 per share

Profitability

Net Income$-112,360,000.00
Net Margins-642.70%

Miscellaneous

Employees101
Market Cap$147.51 million
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) released its earnings results on Wednesday, May, 8th. The specialty pharmaceutical company reported ($1.10) EPS for the quarter, beating the Zacks' consensus estimate of ($1.19) by $0.09. The specialty pharmaceutical company had revenue of $1.60 million for the quarter, compared to analysts' expectations of $0.89 million. Paratek Pharmaceuticals had a negative return on equity of 232.61% and a negative net margin of 642.70%. View Paratek Pharmaceuticals' Earnings History.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Paratek Pharmaceuticals.

What price target have analysts set for PRTK?

7 Wall Street analysts have issued twelve-month target prices for Paratek Pharmaceuticals' shares. Their predictions range from $12.00 to $50.00. On average, they anticipate Paratek Pharmaceuticals' stock price to reach $23.7143 in the next year. This suggests a possible upside of 421.2% from the stock's current price. View Analyst Price Targets for Paratek Pharmaceuticals.

What is the consensus analysts' recommendation for Paratek Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Paratek Pharmaceuticals.

What are Wall Street analysts saying about Paratek Pharmaceuticals stock?

Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (5/15/2019)
  • 2. HC Wainwright analysts commented, "916-3963, Probability of success (POS) Risk-adj value Full value Rating NUZYRA – ABSSSI 100.0% $9.34 $9.34 Shares outstanding 32,285 S/O as of December 31, 2018." (2/28/2019)

Has Paratek Pharmaceuticals been receiving favorable news coverage?

Media headlines about PRTK stock have trended positive recently, InfoTrie reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.

Who are some of Paratek Pharmaceuticals' key competitors?

What other stocks do shareholders of Paratek Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Mattel (MAT), Ultra Clean (UCTT), General Electric (GE), Exelixis (EXEL), Verastem (VSTM), Twitter (TWTR), Progenics Pharmaceuticals (PGNX), Energy Transfer LP Unit (ET), General Motors (GM) and TG Therapeutics (TGTX).

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael F. Bigham, Chairman & CEO (Age 61)
  • Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 60)
  • Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 57)
  • Mr. Adam Woodrow, Chief Commercial Officer & VP (Age 52)
  • Mr. Douglas W. Pagán, Consultant (Age 47)

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.04%), Northern Trust Corp (1.26%), Water Island Capital LLC (1.13%), Water Island Capital LLC (1.13%), JPMorgan Chase & Co. (0.92%) and Renaissance Technologies LLC (0.89%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Robert S Radie, Thomas John Dietz and William M Haskel. View Institutional Ownership Trends for Paratek Pharmaceuticals.

Which institutional investors are selling Paratek Pharmaceuticals stock?

PRTK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Morgan Stanley, JPMorgan Chase & Co., Quinn Opportunity Partners LLC, Wedbush Securities Inc., Raymond James & Associates and Charles Schwab Investment Management Inc.. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Thomas John Dietz and William M Haskel. View Insider Buying and Selling for Paratek Pharmaceuticals.

Which institutional investors are buying Paratek Pharmaceuticals stock?

PRTK stock was purchased by a variety of institutional investors in the last quarter, including Water Island Capital LLC, Water Island Capital LLC, Parametric Portfolio Associates LLC, Trellus Management Company LLC, State of Wisconsin Investment Board, BNP Paribas Arbitrage SA, Wells Fargo & Company MN and Swiss National Bank. View Insider Buying and Selling for Paratek Pharmaceuticals.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $4.55.

How big of a company is Paratek Pharmaceuticals?

Paratek Pharmaceuticals has a market capitalization of $147.51 million and generates $17.12 million in revenue each year. The specialty pharmaceutical company earns $-112,360,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is http://www.paratekpharma.com.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]


MarketBeat Community Rating for Paratek Pharmaceuticals (NASDAQ PRTK)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  336 (Vote Outperform)
Underperform Votes:  286 (Vote Underperform)
Total Votes:  622
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel